Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 23339

Drug Profile

BGB 23339

Alternative Names: BGB-23339

Latest Information Update: 27 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Anti-inflammatories
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 17 Oct 2022 BeiGene withdraws a phase I clinical trial in healthy volunteers prior to enrolment, as sponsor determined the data was no longer needed (PO, Tablet) (NCT05387668)
  • 15 Sep 2022 BeiGene completes a phase I trial in Inflammation (Monotherapy; In volunteers) in Australia and China (NCT05093270)
  • 26 May 2022 BeiGene plans a phase I pharmacokinetics trial in Japanese and Caucasian (In adults, In volunteers) in June 2022 (PO) (NCT05387668)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top